You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

Citation Tools

Article menu

Download PDFPDF

XML
Research Article
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Vaishampayan U, Schöffski P, Ravaud A, et al
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
Journal for ImmunoTherapy of Cancer 2019;7:275. doi: 10.1186/s40425-019-0746-2